Read more

Laboratoire XO is focused on serving
patients and healthcare professionals

Health in action

Carte présence géographiqueRead more

Our geographical

Our products Innovations and references for healthcare professionals

Our news related to the medical world and health in general

Laboratoire X.O begins a new stage of its growth with the support of Stanley Capital

04 October 2022, London – Stanley Capital Partners (SCP) has invested in a majority stake in French pharmaceutical group Laboratoire XO (Lab XO). Debt was provided by US lending giant Ares Management. Headquartered in Saint Cloud,…

New transaction for Laboratoire XO

Paris, October 29, 2021 - Laboratoire X.O has entered into a transaction with Astellas Pharma Inc. for the rights to nicardipine (3 brands) in 4 European countries. This will strengthen our portfolio of 24 brands and our European footprint. Since…

Laboratoire XO celebrates its 5th anniversary

Laboratoire X.O is a French success story. Our objective? To provide patients and healthcare professionals with innovative, qualitative products of real therapeutic interest. The story began in 2015 with the acquisition of 2 brands identified…

Laboratoire XO launches its brand new mouthwash

As part of the extension of Laboratoire X.O's range of OTC products, a new range of cosmetic mouthwashes with disruptive flavours has been launched: Prexifresh Mango & Mint. This is a daily treatment whose objective is to reduce the…

With our strong base in the French market, we see tremendous opportunity for continued growth both in France and internationally.  The management team and myself have been impressed by Stanley  Capital’s vision for the business, their expertise and their connections in the pharmaceutical world.

I am really excited to continue the development of LXO with Stanley Capital and I’m convinced that we will reach our common vision to reinforce our position as  a robust pharma company specialized in acquiring and developing sales of established essential products for patients health, and perceived as a partner of choice by several big pharmas for their licensing-out options.

Laboratoire X.O undertakes to comply with the Promotional Information Charter and the Certification Standards in force. The person carrying out an information activity by canvassing or prospecting whom you have met is able to introduce you and answer questions concerning the rules of ethics with which he/she must comply in relation to health professionals.

In addition, you have the possibility of expressing your opinion on the information provided to you, in particular its scientific and medico-economic quality, its objectivity and its compliance with the laws and regulations in force as well as with the Charter, at the following e-mail address:

Logo Bureau Veritas

© 2022 Réalisé par TA - Legal notice General conditions of use Medicines promotion charter Laboratoire X.O has a quality policy for promotional information available on request at SI_LAXO_02-112020